The Cancer Research Machine Trump Is Gutting Just Delivered a Big Breakthrough
A recent breakthrough in pancreatic cancer treatment was announced at a Chicago convention, where a new drug called daraxonrasib was shown to nearly double survival time for patients. Despite this promising development, concerns arise as the Trump administration's funding cuts threaten future cancer research. The findings highlight both the potential for progress in treating previously deemed 'undruggable' cancers and the risks posed by reduced federal support for scientific research.
- ▪Daraxonrasib has nearly doubled survival time for pancreatic cancer patients who have undergone chemotherapy.
- ▪Patients treated with daraxonrasib survived an average of 13.2 months compared to 6.7 months with standard secondary chemotherapy.
- ▪The Trump administration has been criticized for undermining federal funding for scientific research, which could impact future cancer breakthroughs.
The Bulwark files mainly under politics. We currently carry 336 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Bulwark |
| Canonical URL | https://www.thebulwark.com/p/cancer-research-machine-trump-is-gutting-just-delivered-big-breakthrough-pancreatic-cancer-daraxonrasib |
| Publication time | Wed, 03 Jun 2026 00:50:30 GMT |
| Retrieval time | 2026-06-03T01:36:59.801Z |
| Last seen | 2026-06-03T01:36:59.801Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | BoID8PWz2ptQ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The BreakdownThe Cancer Research Machine Trump Is Gutting Just Delivered a Big BreakthroughThere’s new hope for one of the deadliest cancers. But Trump’s war on research puts future discoveries at risk.Jonathan CohnJun 03, 2026332527Share(Photo illustration by The Bulwark / Photos: Getty)IT IS NOT EASY TO OVERWHELM CANCER SCIENTISTS, a world-weary bunch who are constantly dealing with setbacks in their experiments—and, all too frequently, deaths among their patients. But it happened on Sunday morning, inside a darkened Chicago convention hall, when Harvard-based researcher Brian Wolpin announced the results of clinical trials for a drug called daraxonrasib.Wolpin spoke in a monotone, addressing fellow oncologists from around the world.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Bulwark.
Discussion
0 commentsMore from The Bulwark
